NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









NanoPhoria Bioscience

NanoPhoria Bioscience

Private
MilanHealthcare & Life Scienceshttps://www.nanophoria.com/

Last Round

Series A

Oct 6, 2025

Total Funding Raised

$135.95M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

NanoPhoria Bioscience is a biopharmaceutical company developing a non-viral drug delivery platform using inorganic nanoparticles to provide treatments for heart failure.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Medical Devices

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

drug delivery platforminhalable therapyheart failure with reduced ejection fractionHFrEFnanoparticle drug deliverybiologics deliverycardiovascular therapeuticsdry powder formulationpeptide therapeuticsdrug delivery techpulmonary drug deliverybiotech startuppreclinical biotechnanomedicinedrug development

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

NanoPhoria Bioscience Comparables

Compare NanoPhoria Bioscience with similar companies based on industry and business-model similarity.

NanoPhoria Bioscience comparables — related companies by embedding similarity
CompanySimilarityMarket Cap

View Full Comparables Set

Access detailed peer comparisons, similarity scores, and market data.

NanoPhoria Bioscience Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AOct 6, 2025
GrantFeb 25, 2025
SeedMay 11, 2022

Key People

Founding team and executive leadership

Claudio De Luca

Co-Founder Chief Executive Officer

Founding Team

NanoPhoria Bioscience Investors

Notable investors and investment history

NanoPhoria Bioscience investors
InvestorRounds
European Innovation CouncilSeries A, Grant
XGEN VentureSeries A
CDP Venture Capital SGRSeries A
Panakès PartnersSeries A
Sofinnova PartnersSeries A, Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 27, 2026

    Grew 33% QoQ from 12 to 16 employees.

  • Feb 25, 2025

    Secured $20M from the European Innovation Council.

NanoPhoria Bioscience Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

NanoPhoria Bioscience Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about NanoPhoria Bioscience's valuation, stock price, and market status.

Firmographic Details

HeadquartersMilan
Employee Range17
Year Founded2022
Last FundingOct 6, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.